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terms of observable characteristics such as age, gender, and comorbidities
(p0.001). Samples were balanced with nearest neighbor matching. Then seg-
mented time-series models were applied. There was a significant association be-
tween the onset of intervention and the level of utilization of these drugs.
CONCLUSIONS: To isolate the effects of guidelines, we need to control for three
different factors: 1) baseline differences between the two groups; 2) stepwise dif-
ferences at the intervention point; and 3) trend differences after the intervention.
We showed that propensity scorematching can be used for the first factor, and the
latter two can be controlled with the interrupted time-series model.
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OBJECTIVES: The burden of caregiving is high. In 2009 therewere an estimated 65.7
million caregivers in the U.S. (29% of the adult population) and these numbers are
expected to swell in the coming years with the ageing population. Caregiving im-
pacts on the health, wellbeing and work productivity of the caregiver, therefore
research aimed at assessing and reducing the burden of caregiving is warranted.
The objective of this study was to assess the status of current clinical research into
the burden of caregiving. METHODS: Clinicaltrials.gov was searched for trials
where caregiver burden (CB) was reportedly measured. Information on the care-
recipient condition (CRC), the primary focus of the study, and the type of interven-
tion being considered, was extracted from the included trials. RESULTS: 80 trials
were identified that measured a reported outcome of CB. The most common CRC
was Alzheimer’s disease and related disorders (34 studies); followed by cancer (14),
frail and elderly (8), mental health (7), Parkinson’s disease (7), brain and spinal cord
injury (5) and ‘other’ (5). A range of questionnaire-based instruments were report-
edly used across studies to elucidate the physical, emotional (psychological), social
and financial impacts of caregiving.The role or burden of the caregiver was a key
focus in 55% of the studies; trials involving care of cancer patients had the highest
proportion of caregiver-focused studies (12/14, 86%). Behavioural and drug inter-
ventions were the most frequently investigated intervention type (38% and 25% of
trials, respectively), although no studies investigating a ‘drug’ intervention evalu-
ated the effect on caregivers as a primary outcome. CONCLUSIONS: Current clini-
cal research into the burden of informal caregiving is concentrated in age-related
CRCs. Research interventions aimed at relieving CB are mostly behavioural in na-
ture. The growing number of caregivers means that research into effective meth-
ods of reducing CB will be of ever increasing importance.
Research on Methods – Cost Methods
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OBJECTIVES: The increasing popularity of Complementary and Alternative Medi-
cine (CAM) leading to an increasing interest of CAM assessment through phar-
macoeconomic evaluation. The attempts, however, have been unsatisfactory. This
study attempted to survey expert practitioners in China of TCM (Traditional Chi-
nese Medicine) which is a major part of CAM to elucidate critical issues when
assessing cost-effectiveness of TCM, and to ascertain influencing factors of mea-
suring HR-QOL in TCM. METHODS: A questionnaire (with 20 close and open-end
questions) was distributed to TCM practitioners who had been working in the field
for at least 5 years and had published at least one related paper in the last 5 years.
The questions were divided into two modules with module 1 about the issues of
pharmacoeconomic of TCM, andmodule two about the influencing factors of mea-
suring HR-QOL in TCM. Correlation and Partial Correlate test using age and profes-
sional field as control variable were used to module 1 and 2 respectively, non-
related factors were excluded. Principal Component Analysis (PCA) was performed
for remaining items. RESULTS: Of 429 questionnaires issued, 137 were recovered
from 31 medical and research institutions of 8 provinces and cities in China giving
a recovered rate 31.93%. Module 1 and 2 all passed the KMO and Bartlett’s test of
sphericity test (kmomodule 10.56, kmomodule 20.66). Module 1 extracted 4 common
factors after the Rotation Factor Analysis with cumulative variance of 69.9%, while
Moduel 2 extracted 3 with cumulative variance of 70.6%. CONCLUSIONS: The com-
mon factors fromModule 1 prompted us to pay attention to during the pharmaco-
economic evaluation: patient preference; long-term outcomes; the alternative of
TCM; and the overall economic burden of patients.The common factors fromMod-
ule 2 required us to note during the HR-QOL research: Acceptance level of the
measurement scale by patients and physicians; disease complexity; and whether
HR-QOL scale reflects the characteristics of TCM.
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OBJECTIVES: The primary objective is a review, classification and critical appraisal
of contingent valuationmethod (CVM) healthcare studies conducted in Sub-Sahara
Africa based on criteria by O’Brien and Gafni (1996). The secondary objective is to
determine the impact of the Bamako Initiative adopted in the early 1990s on CVM
studies in the same setting. METHODS: CVM African healthcare studies (willing-
ness to pay (WTP) and willingness to accept (WTA)), were identified using a com-
prehensive literature search in EconoLit, Google Scholar, Medline, PubMed and
Web of Science between 1981 to 2010. CVM studies evaluated included WTP and
WTA studies reporting primary data were included for evaluation. Primary assess-
ment of the studies was based on the conceptual framework for evaluation of
contingent valuation of healthcare programs (5 Items)(O’Brien and Gafni 1996).
Secondary assessment was based on the time horizon of publication: pre-, during-
(1990s), or post- BI, and area of intervention. RESULTS: Twenty-four CVM studies
were evaluated: all used WTP and compensating variation. Elicitation techniques
were dominated by bidding game (42%), followed by dichotomous choice (33%), and
then payment card and the open ended formats (12.5%). Majority of studies (83%)
were published after 2000, the remainder were published in the 1990s. Interven-
tions included insurance (25%), medication (38%), and health services (38%).
CONCLUSIONS: Healthcare CVM studies in Sub-Sahara Africa are limited despite
the introduction of Bamako Initiative. The predominance of the bidding game elic-
itation technique in evaluated studies may be a reflection of the actual African
market conditions. There is continuing debate as to which is the most appropriate
CVM for healthcare studies conducted in Africa This debate will continue until
these methods are compared to actual markets. CVM studies may start to engage
the political market as Africa moves towards universal health coverage.
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OBJECTIVES: The conventional ICER (incremental cost-effectiveness ratio), which
quantifies howmany dollars are spent per QALY (quality-adjusted life year) gained
from a specific health technology, has been criticized as unfair to the aged and/or
physically challenged. METHODS: By taking the position that every life is equally
important and every citizen is entitled to access health care services for the entire
duration of his/her life expectancy, we replace the denominator of the conven-
tional ICER, with the proportion of life, which is the quality-adjusted life expec-
tancy (QALE) gained from the specific health technology divided by the QALE of the
corresponding age- and gender-matched general population. The numerator is
converted to the additional monetary cost spent over a lifetime after adjustment
for annual discount rate. The new indicator quantifies howmany dollars are spent
to save the life of a person with a specific illness, and how much can be saved by
preventing the occurrence of that illness. RESULTS: We have applied the estima-
tion method to compare patients with liver cancer; breast cancer, acquired immu-
nodeficiency syndrome, maintenance hemodialysis and peritoneal dialysis, and
prolongedmechanical ventilation.CONCLUSIONS: Because the proposed indicator
accounts for a fair opportunity for the aged and disabled more than the conven-
tional ICER does, we recommend that this indicator be applied in future delibera-
tions of health care resource allocation.
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OBJECTIVES: Determination of the price of a drug starts in its early developmental
stages and it is driven by various competitive healthmarket forces. The purpose of
the study is to explore associations between pharmaceutical pricing and the value
of drugs. METHODS: Based on FDA indications we have identified three different
drug categories: life saving drugs, drugs that are not life saving but save lives
overtime, and drugs that only treat disease symptoms and affect QOL. We have
investigated our theory of an association between drug intended outcomes and the
price tag placed on a drug by performing a literature review of cost analyses for
drugs selected in each category. The literature review included a combination of
key words such as the name of the drug, cost-effectiveness, cost-utility, and QALY.
We identified articles from the past 10 years published only in the English lan-
guage. For each drug, studies reporting ICER/QALY values were selected. ICER/
QALY data were recorded and the values of the three categories were compared
among each other and with the published acceptable QALY threshold value of
US$64,000.RESULTS: For the life saving drugs group the highest ICER/QALY value is
US$150,843 and lowest is €6,880, for the disease ameliorating drugs group €105,599
and US$544, and for the drugs treating disease symptoms and affecting QOL
£154,831 and $US1,056 respectively. Themajority of drugs in the first categorywere
found to have ICER/ QALY values greater than the $64,000 value, while themajority
of the drugs selected in the second and third categories were found to have ICER/
QALY values smaller than the $64,000 value. CONCLUSIONS: From our study we
have found that drugs that are life saving aremore likely to have ICER/QALY values
greater than the threshold values compared to drugs that are disease ameliorating
and that are designed to improve patients’ QOL.
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OBJECTIVES: In contrast to theNational Institute for Health and Clinical Excellence
(NICE), the German Institute for Quality and Efficiency in Health Care (IQWiG) does
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